Follicular Lymphoma

Novartis announced that the study met its primary end point of complete response rate in patients with relapsed or refractory follicular lymphoma.

The FDA approved tazemetostat for adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, as well as for adult patients with relapsed or refractory FL who have no satisfactory alternative treatment options.

The FDA granted regenerative medicine advanced therapy designation to tisagenlecleucel for an investigational new indication to treat patients with relapsed or refractory follicular lymphoma.